Allogene Therapeutics, Inc.
ALLO
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The companā¦ read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.84
Price-2.13%
-$0.04
1Y
Price
Market Cap
$635.085m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR-58.9%
3y CAGR-54.0%
5y CAGREarnings
-$173.760m
+9.0%
1y CAGR+18.7%
3y CAGR+15.0%
5y CAGREPS
-$0.77
+11.5%
1y CAGR+27.5%
3y CAGR+23.7%
5y CAGRBook Value
$278.875m
$395.958m
Assets$117.083m
Liabilities$81.051m
DebtDebt to Assets
20.5%
-0.5x
Debt to EBITDAFree Cash Flow
-$109.526m
+26.8%
1y CAGR+22.8%
3y CAGR+15.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company